Physician profile
Bailey Berry
NPI 1427639731
$2,426.67
in general payments reported to CMS, 2019-2025
27 companies · $839 in 2025
The $839 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $293 · 2022: $394 · 2024: $900 · 2025: $839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.66 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $410.73 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $333.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $237.57 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $230.10 | 2024-2025 | Veozah |
| Abbvie INC. | $149.43 | 2021-2025 | |
| Pfizer INC. | $130.73 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $124.95 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.34 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.41 | 2022-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $71.82 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $59.89 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $58.64 | 2022-2025 | |
| Corcept Therapeutics | $55.49 | 2025 | Korlym |
| Shield Therapeutics INC | $51.94 | 2024 | |
| Glaxosmithkline, LLC. | $43.15 | 2021-2024 | Trelegy Ellipta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $30.00 | 2024 | Rexulti |
| Amgen INC. | $29.56 | 2021-2025 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $24.24 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $23.98 | 2021 | |
| Phathom Pharmaceuticals, INC. | $22.02 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $21.40 | 2025 | Inspire |
| Collegium Pharmaceutical, INC. | $20.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.54 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.74 | 2025 | |
| Sanofi-Aventis U.S. LLC | $15.75 | 2022 | |
| Vistapharm, INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.